Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.49 |
| ▸ | PDE2A | O00408 | 5/20 | 0.42 |
| ▸ | EGFR | P00533 | 4/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15567659 | 1.00 | TRPM8 (0.49) | TRPM8PDE2AEGFRFGFR1KDR | |
| SCHEMBL16414044 | 0.92 | TRPM8 (0.48) | TRPM8PDE2AEGFRFGFR1KDR | |
| SCHEMBL15567748 | 0.92 | TRPM8 (0.48) | TRPM8PDE2AEGFRFGFR1KDR | |
| SCHEMBL16414048 | 0.92 | TRPM8 (0.48) | TRPM8PDE2AEGFRFGFR1KDR | |
| SCHEMBL15567746 | 0.92 | TRPM8 (0.48) | TRPM8PDE2AEGFRFGFR1KDR | |
| SCHEMBL15566803 | 0.91 | TRPM8 (0.51) | TRPM8PDE2AEPHX2TRPV1NAMPT | |
| SCHEMBL15566807 | 0.91 | TRPM8 (0.51) | TRPM8PDE2AEPHX2TRPV1NAMPT | |
| SCHEMBL15567307 | 0.91 | TRPM8 (0.48) | TRPM8PDE2AEPHX2TRPV1NAMPT | |
| SCHEMBL15567305 | 0.91 | TRPM8 (0.48) | TRPM8PDE2AEPHX2TRPV1NAMPT | |
| SCHEMBL15567476 | 0.91 | TRPM8 (0.51) | TRPM8PDE2AEPHX2TRPV1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | claimed |
| WO-2014025651-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC. (US) | 2014-02-13 | — | — | WO | claimed |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | disclosed |
| WO-2014025651-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC. (US) | 2014-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | TRPM8 1/4885PDE2A 891/4885EGFR 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.